Alpine Global Management, LLC Galectin Therapeutics Inc Transaction History

Alpine Global Management, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$2.13 - $4.2 $41,652 - $82,131	19,555 New	19,555 $44,000
Q2 2019 Jul 12, 2019	SELL	$3.61 - $5.0 $68,925 - $95,465	-19,093 Closed	0 $0
Q1 2019 May 10, 2019	SELL	$3.86 - $6.02 $16,435 - $25,633	-4,258 Reduced 18.23%	19,093 $98,000
Q4 2018 Feb 14, 2019	BUY	$3.43 - $5.74 $80,093 - $134,034	23,351 New	23,351 $80,000

9.65M

1.16M

1.98M

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $123M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

Get notified when there are updates to the investment portfolio of Alpine Global Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Alpine Global Management, LLC with notifications on news.